Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 27;12(9):969.
doi: 10.3390/vaccines12090969.

Immunogenicity and Safety of Chikungunya Vaccines: A Systematic Review and Meta-Analysis

Annalisa Rosso  1 , Maria Elena Flacco  1 , Giovanni Cioni  1 , Marco Tiseo  1 , Gianmarco Imperiali  1 , Alessandro Bianconi  2 , Matteo Fiore  2 , Giovanna Letizia Calò  1 , Vittorio Orazi  1 , Anastasia Troia  1 , Lamberto Manzoli  2
Affiliations
Review

Immunogenicity and Safety of Chikungunya Vaccines: A Systematic Review and Meta-Analysis

Annalisa Rosso et al. Vaccines (Basel). .

Abstract

Several vaccines against chikungunya fever have been developed and tested, and one has been recently licensed. We performed a meta-analysis to estimate the immunogenicity and safety of all chikungunya vaccines that have been progressed to clinical trial evaluation (VLA1553; mRNA-1388/VAL-181388; PXVX0317/VRC-CHKVLP059-00-VP; ChAdOx1 Chik; MV-CHIK). We included trials retrieved from MedLine, Scopus, and ClinicalTrials.gov. The outcomes were the rates of seroconversion/seroresponse and serious adverse events (SAEs) after the primary immunization course. We retrieved a total of 14 datasets, including >4000 participants. All candidate chikungunya vaccines were able to elicit an immunogenic response in ≥96% of vaccinated subjects, regardless of the vaccination schedule and platform used, and the seroconversion/seroresponse rates remained high 6 to 12 months after vaccination for most vaccines. Four of the five candidate vaccines showed a good overall safety profile (no data were available for ChAdOx1 Chik), with no significant increase in the risk of SAEs among the vaccinated, and a low absolute risk of product-related SAEs. Overall, the present findings support the potential use of the candidate vaccines for the prevention of chikungunya and the current indication for use in adult travelers to endemic regions of the licensed VLA 1553 vaccine. In order to extend chikungunya vaccination to a wider audience, further studies are needed on individuals from endemic countries and frail populations.

Keywords: MV-CHIK; VLA1553; VRC-CHKVLP059-00-VP; chikungunya fever; chikungunya vaccine; immunogenicity; meta-analysis; vaccine safety.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
PRISMA 2009 Flow Diagram [14].
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Wahid B., Ali A., Rafique S., Idrees M. Global expansion of chikungunya virus: Mapping the 64-year history. Int. J. Infect. Dis. 2017;58:69–76. doi: 10.1016/j.ijid.2017.03.006. - DOI - PubMed
    1. Rama K., de Roo A.M., Louwsma T., Hofstra H.S., Amaral G.S.G.D., Vondeling G.T., Postma M.J., Freriks R.D. Clinical outcomes of chikungunya: A systematic literature review and meta-analysis. PLoS Neglected Trop. Dis. 2024;18:e0012254. doi: 10.1371/journal.pntd.0012254. - DOI - PMC - PubMed
    1. Paixao E.S., Rodrigues L.C., Costa M., Itaparica M., Barreto F., Gerardin P., Teixeira M.G. Chikungunya chronic disease: A systematic review and meta-analysis. Trans. R. Soc. Trop. Med. Hyg. 2018;112:301–316. doi: 10.1093/trstmh/try063. - DOI - PubMed
    1. Bettis A.A., L’Azou Jackson M., Yoon I.K., Breugelmans J.G., Goios A., Gubler D.J., Powers A.M. The global epidemiology of chikungunya from 1999 to 2020: A systematic literature review to inform the development and introduction of vaccines. PLoS Neglected Trop. Dis. 2022;16:e0010069. doi: 10.1371/journal.pntd.0010069. - DOI - PMC - PubMed
    1. Ryan S.J., Carlson C.J., Mordecai E.A., Johnson L.R. Global expansion and redistribution of Aedes-borne virus transmission risk with climate change. PLoS Neglected Trop. Dis. 2019;13:e0007213. doi: 10.1371/journal.pntd.0007213. - DOI - PMC - PubMed

Grants and funding

This research received no external funding.

LinkOut - more resources